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Aneuploid Acute Myeloid Leukemia Exhibits a Signature of 
Genomic Alterations in the Cell Cycle and Protein Degradation 
Machinery
Giorgia Simonetti1; Antonella Padella1; Italo Farìa do Valle2,3; Maria Chiara Fontana1; Eugenio Fonzi1; Samantha Bruno1; 
Carmen Baldazzi1; Viviana Guadagnuolo1; Marco Manfrini1; Anna Ferrari1; Stefania Paolini1; Cristina Papayannidis1; 
Giovanni Marconi1; Eugenia Franchini1; Elisa Zuffa1; Maria Antonella Laginestra1; Federica Zanotti1; Annalisa Astolfi4; 
Ilaria Iacobucci1; Simona Bernardi5; Marco Sazzini6; Elisa Ficarra7; Jesus Maria Hernandez8; Peter Vandenberghe9;  
Jan Cools9; Lars Bullinger10; Emanuela Ottaviani1; Nicoletta Testoni1; Michele Cavo1; Torsten Haferlach11;  
Gastone Castellani2; Daniel Remondini2; and Giovanni Martinelli1
BACKGROUND: Aneuploidy occurs in more than 20% of acute myeloid leukemia (AML) cases and correlates with an adverse prognosis. 
METHODS: To understand the molecular bases of aneuploid acute myeloid leukemia (A-AML), this study examined the genomic profile 
in 42 A-AML cases and 35 euploid acute myeloid leukemia (E-AML) cases. RESULTS: A-AML was characterized by increased genomic 
complexity based on exonic variants (an average of 26 somatic mutations per sample vs 15 for E-AML). The integration of exome, copy 
number, and gene expression data revealed alterations in genes involved in DNA repair (eg, SLX4IP, RINT1, HINT1, and ATR) and the cell 
cycle (eg, MCM2, MCM4, MCM5, MCM7, MCM8, MCM10, UBE2C, USP37, CK2, CK3, CK4, BUB1B, NUSAP1, and E2F) in A-AML, which was 
associated with a 3-gene signature defined by PLK1 and CDC20 upregulation and RAD50 downregulation and with structural or func-
tional silencing of the p53 transcriptional program. Moreover, A-AML was enriched for alterations in the protein ubiquitination and deg-
radation pathway (eg, increased levels of UHRF1 and UBE2C and decreased UBA3 expression), response to reactive oxygen species, 
energy metabolism, and biosynthetic processes, which may help in facing the unbalanced protein load. E-AML was associated with 
BCOR/BCORL1 mutations and HOX gene overexpression. CONCLUSIONS: These findings indicate that aneuploidy-related and leukemia-
specific alterations cooperate to tolerate an abnormal chromosome number in AML, and they point to the mitotic and protein degrada-
tion machineries as potential therapeutic targets. Cancer 2019;125:712-725. © 2018 The Authors. Cancer published by Wiley Periodicals, 
Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, 
the use is non-commercial and no modifications or adaptations are made. 
KEYWORDS: acute myeloid leukemia, aneuploidy, cell cycle, genomics, mutation, ubiquitination, whole exome sequencing
INTRODUCTION
Aneuploidy originates from defects in chromosome segregation and is detrimental to organism fitness and develop-
ment.1,2 At the cellular level, it induces transcriptional reprogramming2,3, mitotic and proteotoxic stress and meta-
bolic alterations,1,4,5 and it impairs proliferation in hematopoietic stem cells, among others.6 As such, aneuploidy 
per se seems to hamper malignant transformation. However, aneuploidy is a hallmark of cancer.7 More than 20% 
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of acute myeloid leukemia (AML) cases carry a whole-
chromosome trisomy/monosomy either alone or in 
combination with other cytogenetic abnormalities.8,9 
Chromosome gains and losses are generally preserved 
from diagnosis to relapse, and this supports their role as 
disease-initiating events.10 Moreover, monosomies (eg, 
−7) and the monosomal karyotype (MK) predict dismal 
outcomes,9 and isolated trisomies have in some but not 
all series been associated with an adverse prognosis.8,11,12
The study of the genomic determinants of aneu-
ploidy is a very active research field. A number of genes 
and pathways participate to prevent aneuploidy propaga-
tion. Beside TP53, a guardian of ploidy,13 candidate genes 
are involved in the mitotic checkpoint, DNA damage 
response, and recombination.14 However, they are rarely 
mutated in AML, and their deregulated expression in mice 
can either favor or hamper tumor development according 
to the presence of threshold levels, the cell type, and the 
genomic background.15 Recent studies have analyzed the 
molecular profile of aneuploid acute myeloid leukemia 
(A-AML) subsets. Isolated trisomy 13 is associated with 
RUNX1, ASXL1, BCOR, and spliceosome-complex mu-
tations, upregulated FOXO1 and FLT3 expression, and 
downregulated SPRY expression.12,16 AML with trisomy 
8 shows recurrent ASXL1 and RUNX1 mutations17 and 
deregulation of cell adhesion and apoptosis-regulating 
genes.18 CUX1 is a haploinsufficient tumor suppressor 
in –7/del(7q) cases,19,20 and monosomy 7 AML displays 
elevated ID1, MECOM, and PTPRM.21 This evidence 
suggests that leukemia-specific and aneuploidy-related 
mechanisms may cooperate in the selection of evolved 
clones able to overcome the unfitness barrier of aneuploidy.
To elucidate the molecular mechanisms associ-
ated with A-AML, we have analyzed the genomic and 
transcriptomic landscape of A-AML and euploid acute 
myeloid leukemia (E-AML). We show that A-AML is 
characterized by genomic complexity and by a cell cycle–
related pattern of somatic mutations and copy number 
(CN) and transcriptomic changes along with alterations 
in the protein ubiquitination and degradation machinery 
and downregulation of the p53 transcriptional program.
MATERIALS AND METHODS
Patients
Samples were obtained from patients with AML after informed 
consent as approved by the institutional ethics committees 
(Sant’Orsola-Malpighi Hospital [protocols 253/2013/O/Tess 
and 112/2014/U/Tess] and Munich Leukemia Laboratory 
[an internal board and standard operating procedure EN ISO 
15189]) in accordance with the Declaration of Helsinki.
Chromosome Banding Analysis
Karyotypes were examined after G-banding and were de-
scribed according to the International System for Human 
Cytogenomic Nomenclature (2016).
Whole Exome Sequencing (WES) and 
Identification of Somatic Mutations
Libraries were prepared from matched tumor/germline 
DNA of 77 patients (TruSeq Exome Enrichment Kit 
or Nextera Rapid Capture Expanded Kit; Illumina, 
Inc) according to the manufacturer’s protocol, and 
100-bp paired-end sequences were generated (Illumina 
HiSeq1000 or HiScanSQ). Tumor-specific variants were 
called by MuTect and VarScan 2. The pipeline was vali-
dated with Sanger DNA sequencing and targeted rese-
quencing (Supporting Table 11).
Analysis of WES Data From The Cancer 
Genome Atlas (TCGA) Data Set
The TCGA data set contains genomic data for 200 adult 
patients with AML.22 WES and clinical data were down-
loaded from the Genomic Data Commons data portal 
(https://gdc.cancer.gov). According to available cytogenetic 
information, we were able to define 21 TCGA A-AML cases 
and 116 TCGA E-AML cases. Complex karyotype (CK) 
cases were excluded in the absence of detailed information 
on chromosome number alterations (monosomy5/del(5q) 
and monosomy7/del(7q)). The TCGA A-AML cohort in-
cluded 11 cases with isolated trisomy (1 case of trisomy 21 
and 10 cases of trisomy 8) and 10 cases with CK-AML.
Copy Number Alteration (CNA) Analysis
A genome-wide CN analysis was performed with Human 
CytoScan HD or SNP6.0 arrays (Affymetrix).
Enrichment Analysis
CNA events at the gene level were tested for an associa-
tion with the aneuploid (A)/euploid (E) condition with 
the Fisher exact test. An overrepresentation test (based 
on a hypergeometric distribution) of each pathway was 
performed at the patient level. P values obtained for a 
certain pathway across all patients were used as predic-
tor variables in a logistic regression model fitted against 
the A-AML/E-AML classification. Heterozygous and 
homozygous amplifications were grouped as well as 
heterozygous and homozygous deletions; multiple events 
of the same type in the same gene were considered as 
one. P values were adjusted for multiple testing (false 
discovery rate < 0.05; 99.9999% confidence interval). 
An overrepresentation analysis of cytogenetic bands was 
performed.
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Gene Expression Profiling (GEP)
Labeled complementary DNA was prepared and hy-
bridized to GeneChip Human Transcriptome Array 
2.0 (Affymetrix) according to the manufacturer’s 
recommendations.
RESULTS
Genomic Complexity of A-AML
To investigate the genetic lesions associated with the ane-
uploid phenotype, we performed WES of 42 A-AML 
cases and 35 E-AML cases (Table 1 and Supporting 
Table 1). Patients with A-AML were older (median age, 
62 vs 56 years for patients with E-AML; P = .02), and 
most of them had an adverse prognosis according to the 
2017 European LeukemiaNet recommendations.23
A-AML had a significantly higher mutation load 
with an average number of somatic mutations of 26 (15 
for E-AML; P < .001; Fig. 1A and Supporting Table 2). 
More than 50% of A-AML cases displayed 20 or more 
mutations, whereas 17% of E-AML cases did (P = .002; 
Fig. 1B). In silico analysis indicated that 11 and 7 amino 
acid substitutions on average had an impact on protein 
function in A-AML and E-AML, respectively (P = .008). 
To validate our results in an independent patient cohort, 
we analyzed WES data from the TCGA data set. The in-
creased number of mutations in A-AML was confirmed in 
the TCGA-AML data set (16 and 12 mutations in A-AML 
and E-AML, respectively; P = .027); no differences were 
detected in terms of patients’ ages between the 2 cohorts. 
To characterize the possible relation between the mutation 
number and patients’ ages, we performed linear regression 
analyses in A-AML and E-AML separately. We observed a 
significant age-related increase in the mutation load only 
in A-AML both in our cohort and in the TCGA data set 
(Supporting Fig. 1). Moreover, no significant difference in 
the number of somatic mutations was observed between 
CK–A-AML and non-CK–A-AML cases in both cohorts. 
Taken together, the data suggest a higher complexity for 
the A-AML mutational background.
Patterns of Gene Mutations in A-AML and 
E-AML
Genes recurrently mutated in A-AML and E-AML included 
DNMT3A, IDH2, KRAS, and FLT3 (Fig. 1C). TP53 was dif-
ferentially mutated in A-AML (28.6% vs 2.9% in E-AML; 
P = .004), whereas E-AML was significantly enriched for 
mutations of BCOR/BCORL1 in our cohort (14.3% vs ab-
sent in A-AML; P = .02) and for mutations of NPM1 in the 
TCGA cohort (39.7% vs 9.5% in A-AML; P = .007).
TABLE 1. Characteristics of A-AML and E-AML Cohorts Analyzed With Whole Exome Sequencing
Variable A-AML (n = 42) E-AML (n = 35) P
Sex, No. (%)
Male 20 (47.6) 14 (40.0) .645
Female 22 (52.4) 21 (60.0)
Age, y
Median 62 56 .017
Range 20-83 18-80
Sample type, No.
Bone marrow 38 34 .369
Peripheral blood 4 1
AML, No. (%)
De novo 34 (81.0) 22 (62.9) .182
t-AML 4 (9.5) 5 (14.3)
Secondary 4 (9.5) 8 (22.8)
FAB, No. (%)
M0-M1 13 (31.0) 8 (22.9) .551
M2-M4 12 (28.6) 15 (42.9)
M5-M7 6 (14.3) 3 (8.6)
NA 11 (26.2) 9 (25.7)
Disease stage, No.
Diagnosis 40 34 1
Relapse 2 1
Genetic group, No. (%)
Favorable 8 (19.0) 7 (20.0) <.001
Intermediate 6 (14.3) 21 (60.0)
Adverse 28 (66.7) 7 (20.0)
Abbreviations: A-AML, aneuploid acute myeloid leukemia; AML, acute myeloid leukemia; E-AML, euploid acute myeloid leukemia; FAB, French-American-
British; NA, not available; t-AML, therapy-related acute myeloid leukemia; y, years; No., number.
Bolded P values are significant.
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To better investigate the role of the mutated genes in 
aneuploidy, we compared the percentages of A-AML and 
E-AML cases carrying at least 1 lesion in each functional 
category (Fig. 2A). Tumor suppressor genes were prefer-
entially mutated in A-AML (31.0% vs 2.9% in E-AML; 
P = .002) along with genes involved in the trafficking of 
proteins between cellular compartments (50% vs 22.9% 
in E-AML; P = .02; Supporting Fig. 2 and Supporting 
Table 3), ubiquitination (45.2% vs 20% in E-AML; 
P = .029; Supporting Fig. 3 and Supporting Table 3), 
cell adhesion (42.9% vs 11.4% in E-AML; P = .003; 
Supporting Fig. 4 and Supporting Table 3), and the cell 
cycle (69.0% vs 31.4% in E-AML; P = .001; Fig. 1C and 
Fig. 2A). Notably, A-AML was enriched for mutations 
with a predicted functional impact on ubiquitination 
(P = .05) and the cell cycle (P = .04).
Cell cycle–related mutations were enriched in 
A-AML independently of karyotypic complexity and 
Figure 1. Genomic lesions in A-AML and E-AML. (A) Number and type of nonsilent somatic mutations detected by whole exome 
sequencing. (B) Frequency of A-AML and E-AML cases classified according to the number of mutations. (C) Pattern of genomic 
lesions in A-AML and E-AML. Rows denote genes or group of genes (other). Columns represent (from left to right) functional 
categories (distinguished by colors), mutated genes/groups of genes/other genomic alterations, and single patients. A-AML 
indicates aneuploid acute myeloid leukemia; CN, copy number; E-AML, euploid acute myeloid leukemia; indel, insertion/deletion; 
LOH, loss of heterozygosity; TF, transcription factor.
A-AML E-AML
A B
C
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targeting the same cell cycle phase co-occurred very 
rarely. Few cell cycle–related mutations were also de-
tected in E-AML (Fig. 2C).
These results suggest that deregulated cell cycle 
functionality and changes in protein balance regulation 
may sustain aneuploid leukemic cells.
Mutational Signatures in A-AML and E-AML
To gain insights into the mutational processes active in 
A-AML and E-AML, we analyzed somatic base sub-
stitutions in the 2 cohorts. Both A-AML and E-AML 
showed a preponderance of C>T transitions (37.7% and 
39.7% of overall single-nucleotide variants in A-AML 
Figure 2. Spectrum of somatic mutation categories distinguishing A-AML and E-AML. (A) Frequency of cases carrying mutations 
according to functional categories. Statistical significance was determined with the Fisher exact test (*P < .05; **P < .01). (B) 
Distribution of mutations targeting cell cycle–related genes. Each row denotes 1 gene; columns represent (from left to right) cell 
cycle phases, mutated genes, and single patients. (C) Frequency of mutations according to cell cycle phases. A-AML indicates 
aneuploid acute myeloid leukemia; AML, acute myeloid leukemia; CN, copy number; E-AML, euploid acute myeloid leukemia; 
LOH, loss of heterozygosity.
A
B C
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and E-AML, respectively), as previously reported,24,25 
and they were followed by C>A transversions (26.0% and 
25.1% in A-AML and E-AML, respectively).
Mutational signature analysis revealed that 2 signa-
tures contributed to the mutational diversity of our WES 
cohort (Fig. 3A). Signature 1, which characterized 61.9% 
of A-AML cases and 71.4% of E-AML cases, was domi-
nated by C>T transitions at NpCpG trinucleotides; this 
mutational process has been linked to spontaneous hy-
drolytic deamination of 5-methylcytosines24 and has been 
correlated with age in many cancer types.26 Signature 
2 was characterized by C>A transversions mainly at 
GpCpN sites and was enriched in 38.1% of A-AML cases 
and in 28.6% of E-AML cases (Fig. 3D). Signature 2 con-
tributed to the genomic complexity of 97.6% of A-AML 
cases, whereas 17.1% of E-AML cases were characterized 
by signature 1 only (P = .042; Fig. 3D). Signature 2 was 
associated with an increased disease-related mutation 
load (median number of nonsynonymous single-nucle-
otide variants: 34.5 and 21 in A-AML and E-AML, re-
spectively, with signature 2 enrichment vs 15.5 and 9 in 
A-AML and E-AML, respectively, with signature 1 en-
richment; P = .005).
CNAs in A-AML and E-AML
Data from single-nucleotide polymorphism profiling 
were available for 38 of the 42 patients with A-AML and 
for 32 of the 35 patients with E-AML. When we consid-
ered whole-chromosome and focal CNAs, A-AML was 
significantly associated with CN gains affecting the cell 
cycle; nucleotide biosynthesis; glucose, carbohydrate, and 
amino acid metabolism; bioenergetics; protein assembly 
and degradation; response to reactive oxygen species 
(ROS); stem cell–related pathways; and kinase signaling 
(Supporting Table 4). No differences occurred between 
CK–A-AML and non-CK–A-AML cases.
To prioritize CNAs with a putative role in the an-
euploid phenotype, we considered events with a signifi-
cantly different frequency between the 2 cohorts (Fisher 
exact test) and excluded the events simply caused by 
whole-chromosome trisomy and monosomy. The re-
maining genes defined chromosome cytobands preferen-
tially affected by CNAs in A-AML (P  .05; Supporting 
Table 5). These included minimal common regions in 
chromosomes frequently found to be monosomic or 
trisomic in AML and CNAs in regions rarely targeted 
by whole-chromosome gains and losses (eg, a gain at 
6p12 and a loss at 11p13), where genes involved in the 
aneuploid phenotype likely are localized. In particular, a 
loss of TP53, mapped at 17p13, was detected in 7 A-AML 
cases (P = .01), and the remaining allele was mutated in 6 
of them. One case had mutated TP53 with a loss of het-
erozygosity. Moreover, 6 A-AML cases carried an NPM1 
loss at 5q35 (P = .03), whereas NPM1 mutations were 
detected only in E-AML (Fig. 1C).
Among the CNAs discriminating A-AML and 
E-AML, we identified 40 genes gained and 23 genes in 
lost regions with a known role in AML pathogenesis, 
and we defined hotspots of CN gains localized at 6p22 
and CN losses at 5q31 and 12p13 (P < .05; Supporting 
Table 6). Genes located in the hotspot regions were in-
volved in cell cycle regulation and DNA replication 
(E2F2, KIF20A, CDKN1B, and PURA), double-strand 
break repair (RAD50), chromatin organization (DEK 
and KDM3B), and regulation of the leukemia stem 
cell phenotype and differentiation (SOX4, TIFAB, and 
CTNNA1). For the selected genes, we also computed 
the frequency of co-occurring CN events. A-AML and 
E-AML shared the co-occurrence of a CN loss at 5q with 
a CN gain of the MYB oncogene or the tyrosine protein 
kinase JAK2 (Fig. 4A,B), although the frequency of these 
events was higher in A-AML. Moreover, in A-AML, a loss 
at 5q co-occurred with a gain of MYC or 8q or a TP53 
loss, as previously reported,27 with a loss of CDKN1B 
and the hematopoietic gene ETV6 (chromosome 12), 
and with a CN gain of the regulators of hematopoiesis 
RUNX1 and ERG (chromosome 21), which frequently 
co-occurred (Fig. 4B).
Networks of Genomic Events Characterizing 
A-AML and E-AML
We asked whether overall the genomic events (mutations 
and CNAs) presented with a differential frequency across 
gene ontology biological process pathways in A-AML 
and E-AML. We built networks in which the nodes and 
the links represented the pathways and the number of pa-
tients with enrichment of the 2 pathways, respectively. By 
considering links with a weight ≥ 2 (ie, at least 2 patients 
sharing the same 2 enriched pathways), we identified in 
A-AML and E-AML 165 and 48 nodes and 4768 and 
281 edges, respectively. Genomic alterations in A-AML 
targeted genes derived from many pathways (Supporting 
Fig. 5A), whereas they occurred in a more restricted way 
in patients with E-AML (Supporting Fig. 5B). Genomic 
alterations may disrupt many pathways at once, and 
those most concomitantly affected are highlighted by 
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were detected in 68.2% of CK–A-AML cases and in 
70.0% of non-CK–A-AML cases. They were also en-
riched in the TCGA A-AML cohort (P = .04). They were 
mostly private mutations because alterations in the same 
gene were not recurrent among patients. In A-AML, they 
targeted cell cycle regulators and genes directly involved 
in cell cycle phases (Fig. 2B), with DNA replication and 
the S phase, the G2/M transition, spindle and centro-
some dynamics, and chromosome segregation being the 
most frequently mutated (Fig. 2C). Moreover, mutations 
Figure 3. Mutational signatures in A-AML and E-AML. (A) Mutational signatures according to the 96-substitution classification. 
Mutation types are reported on the horizontal axes with different colors; the percentage of each specific mutation type is 
represented by vertical axes. (B) Contributions of the identified signatures to the mutational processes. A-AML indicates 
aneuploid acute myeloid leukemia; E-AML, euploid acute myeloid leukemia; S1, Signature #1; S2, Signature #2.
A
B
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high degree values in the networks. Regulation of he-
matopoiesis and myeloid cell differentiation were ranked 
among the top disease-related pathways according to 
their degree and betweenness centrality in both A-AML 
and E-AML (Supporting Table 7). Moreover, A-AML 
was characterized by alterations affecting DNA replica-
tion–dependent nucleosome organization and assembly 
and leukocyte differentiation, whereas regulation of the 
Smoothened signaling pathway and cell-matrix adhesion 
distinguished E-AML.
Deregulated Expression of Leukemia-
Specific and Aneuploidy-Related Genes in 
A-AML
To identify transcriptional properties contributing to the 
aneuploid phenotype, we performed GEP of 22 A-AML 
cases and 27 E-AML cases (normal karyotype; Supporting 
Table 1). A principal component analysis of GEP data 
showed no separation between CK–A-AML and non-
CK–A-AML cases (data not shown). A supervised analysis 
identified differential expression of 204 coding genes (56 
upregulated and 148 downregulated) between A-AML 
and E-AML. We detected increased levels of CDKN2C, 
MCM2, and PLK1 and decreased expression of HINT1 
and HOXB5, which were also identified in a previous 
A-AML microarray data set,28 along with overexpression 
of genes associated with chromosome instability in solid 
tumors (MCM2, CDC20, and UBE2C).29
A panel of genes was related to AML pathogenesis 
(Fig. 5A); they included HOX transcription factors, the 
KMT2A partner MLLT10, and the DNA hydroxymeth-
ylation regulator WT1, which showed lower expression 
in A-AML. RUNX3 and the WNT-related gene FRAT2 
were upregulated in A-AML. Additional signaling mol-
ecules showed reduced expression in A-AML; they in-
cluded the inositol 1,4,5-trisphosphate receptor ITPR2, 
the leukemia stem cell marker CD47, the CALM/AF10-
related gene COMMD3, and the RAS pathway genes 
BRAF, PIK3CB, SOS1, and PIK3C3. This suggests 
that distinct molecular mechanisms drive A-AML and 
E-AML.
Notably, A-AML was enriched for upregulated 
genes with known functions in protein modification, 
ubiquitination, metabolic processes, and telomere main-
tenance (Fig. 5B and Supporting Table 8), and this was 
coupled with the downregulation of genes involved in 
macromolecule biosynthesis and nucleic acid metabolic 
processes (Fig. 5B and Supporting Table 9). Such a 
Figure 4. Frequency and co-occurrence of CNAs in leukemia-related genes in (A) euploid acute myeloid leukemia and (B) 
aneuploid acute myeloid leukemia. The Circos plots depict copy number gains/duplications (in red) and loss/deletions (in green) 
in acute myeloid leukemia–related genes associated with the aneuploid phenotype. The bar plots represent the percentages of 
patients with copy number events in each gene (0%-100% scale). Links connect copy number alterations co-occurring in the 
same patient; the color intensity reflects the absolute frequency of patients harboring that co-occurrence (range, 1-17). Mutually 
exclusive alterations may exist in areas that are not connected.
A B
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Figure 5. Gene expression profile analysis of A-AML and E-AML. (A) Gene expression differences in leukemia-related and cell 
cycle– and DNA repair–related genes between A-AML (n = 22) and E-AML (n = 27). Data are standardized through a z-score 
transform; color changes within a row indicate expression levels relative to the mean and rescaled on the transcript standard 
deviation. (B) Biological processes significantly enriched among differentially expressed genes in A-AML versus E-AML (P < 
.05). (C) Percentage of Ki-67+ cells on bone marrow blasts of patients with A-AML and E-AML according to flow cytometry 
analysis. Statistical significance was determined with the Student t test (*P < .05). (D,E) Expression of UHRF1, UBA3, UBE2C, 
RAD50, PLK1, and CDC20 proteins. (D) Western blot of representative cases. (E) Densitometry after normalization for the mean 
value across E-AML. Statistical significance was determined with the Student t test (*P < .05; **P < .01). (F) Signature of p53-
downregulation in A-AML identified by gene set enrichment analysis. A and A-AML indicate aneuploid acute myeloid leukemia; 
E and E-AML, euploid acute myeloid leukemia; ES, enrichment score; NES, normalized enrichment score.
A
B
D
E
C
F
Genomics of Aneuploid AML/Simonetti et al
721Cancer  March 1, 2019
profile may indicate that A-AML cells attempt to face 
the unfavorable aneuploid condition by managing the 
unbalanced protein load and by controlling the prolifera-
tion rate. Indeed, A-AML cases had a reduced percentage 
of Ki-67+ blasts in the bone marrow (23.5% in A-AML 
vs 33.2% in E-AML; P = .03; Fig. 5C) and a lower white 
blood cell count in comparison with E-cases AML both 
in our cohort (median, 7.1 × 109/L for A-AML vs 15.6 × 
109/L for E-AML; P = .038; Supporting Table 1) and in 
the TCGA data set (10.0 × 109/L for A-AML vs 29.5 × 
109/L for E-AML; P = .02).
Transcriptomic Signatures of A-AML
A significant fraction of the differentially expressed genes 
were involved in the cell cycle and DNA repair (Fig. 
5A). These included the DNA damage sensors ATR and 
RAD50 along with the interacting protein RINT1 and 
the positive p53-mediated program regulators DMTF1 
and HINT1, which were downregulated in A-AML. 
Moreover, A-AML showed deregulated expression of 
ubiquitin-related genes involved in cell cycle progres-
sion (Fig. 5A and Supporting Table 8): reduced levels of 
the ubiquitin-activating enzyme UBA3 and upregula-
tion of CCNF, a subunit of the SCF complex; the ubiq-
uitin ligase UHRF1; the ubiquitin-conjugating enzyme 
UBE2C; and CDC20, which regulates APC/C activity. 
The differential expression of these genes was validated 
at the protein level (Fig. 5D,E) except for CCNF, which 
was not confirmed (data not shown). The level of total 
protein ubiquitination did not differ between A-AML 
and E-AML (Supporting Fig. 6). We sought to identify a 
suitable transcriptomic signature of A-AML with thera-
peutic potential. By combining computational analysis 
and biological significance, we defined a 3-gene signa-
ture composed of overexpressed PLK1 and CDC20 and 
downregulated RAD50, which discriminated 73% of 
patients between A-AML and E-AML. RAD50 down-
regulation (P = .041) and PLK1 (P = .024) and CDC20 
upregulation (P = .004) were confirmed at the protein 
level (Fig. 5D,E), and this indicates that a multistep pro-
cess involving different cell cycle phases is finely tuned 
in A-AML.
Gene set enrichment analysis identified a signif-
icant association of A-AML with a gene expression 
signature of p53 deficiency (P = .03; Fig. 5F). This 
finding was particularly relevant because 27% of the 
A-AML cases analyzed with GEP were MK-AML/CK-
AML, and we expected an overall rate of TP53 abnor-
malities of approximately 16% in our A-AML cohort.27 
To verify this hypothesis, we screened the mutational 
hotspots of TP53 by Sanger sequencing. Four of the 22 
patients (18%) carried TP53 genomic alterations (2 mu-
tations and 2 chromosome 17 monosomies; Supporting 
Table 10). The signature enrichment remained signifi-
cant with the exclusion of these cases from the analysis 
(Supporting Fig. 7), and this indicates that nonmuta-
tional p53 inactivation cooperates with structural ab-
normalities to silence the p53 transcriptional program.
DISCUSSION
The study of aneuploidy is of clinical and biological rel-
evance in AML because more than 20% of cases display 
numerical chromosome aberrations,8 which can be asso-
ciated with additional driver mutations.30 However, few 
studies have so far investigated the entire coding genome 
of a limited number of aneuploid cases.12,19,20,31,32 To 
shed light onto the molecular processes associated with 
A-AML, we integrated the analyses of the mutational, 
transcriptional, and CN profiles of a large A-AML cohort 
and compared them with E-AML. This approach high-
lighted A-AML features that were independent of the spe-
cific chromosomal aneuploidy.
Aneuploidy is associated with genomic complexity 
in AML, as observed in solid tumors.33 We found average 
numbers of coding mutations of 26 and 15 per sample in 
A-AML and E-AML, respectively. The average number 
of mutations was higher in our data set in comparison 
with the TCGA cohort because we integrated 2 variant 
calling tools for single-nucleotide variant detection; this 
is a recently suggested strategy for improving cancer ge-
nome analysis.34 We observed a significant age-related 
increase in the mutation number specifically in A-AML. 
This observation rules out (or at least highly reduces) the 
role of age as a potential confounding factor in the study 
and suggests that genomic instability increases with age 
in A-AML. The stress caused by aneuploidy may provide 
a selective pressure toward an accumulation of mutations 
leading to phenotypic changes that enable cells to tolerate 
chromosome imbalances, as observed in different mod-
els.35,36 The reduced number of circulating white blood 
cells and the lower percentage of proliferating bone mar-
row blasts in A-AML may reflect the proliferative disad-
vantage of aneuploid leukemic cells and a more quiescent 
stem cell–like state.37 The overall mutational spectrum of 
A-AML and E-AML was dominated by C>T base sub-
stitutions, as previously reported,24,25 and by signature 
1, which is prevalent in AML and other solid tumors.24 
However, signature 2, which is associated with a higher 
Original Article
722 Cancer  March 1, 2019
mutation load, contributed to the genomic profile of al-
most all A-AML cases, whereas it was not present in a 
fraction of E-AML cases. Future studies of larger AML 
data sets will clarify its role and potential origin in AML.
The integration of the genomic and transcrip-
tomic patterns characterizing A-AML highlights cellu-
lar functions with a potential causal role in aneuploid 
leukemia, including deregulation of cell cycle–related 
processes occurring inside or outside mitosis (Fig. 6). 
Moreover, our data indicate that aneuploidy shapes the 
transcriptional profile of leukemic cells by affecting 
the expression of a set of genes, which is independent 
of the identity of the single chromosomes, as observed 
in aneuploid models.1-3,5 The identified lesions may 
promote genomic instability, hamper cell cycle check-
points, and force its progression.38 Evidence is available 
in the literature for some genes, including BUB1B,39 
NSUN2,40 ESPL1,41 CDK5RAP2,42 NDC1,43 and 
USP44,44 which are mutated in A-AML, and NPM1,45 
which is targeted by CN loss. Among the mutated 
genes, the tumor suppressor TP53 has been associated 
with A-AML30 and CK-AML.27 We show here that the 
p53 transcriptional program is generally silenced in 
A-AML through either structural or functional inacti-
vation, which can be mediated by a number of events,46 
including mutations of the p53 regulators SETD2, 
DDX31, USP10, and USP4, decreased expression of 
DMTF1 and HINT1, and increased levels of PRKCA. 
Reduced expression of RAD50, suggestive of an im-
paired DNA damage response and checkpoint arrest, 
and upregulation of PLK1 may hamper p53 activation 
in A-AML, whereas overexpression of CDC20 could 
help in bypassing the spindle assembly checkpoint 
(Fig. 6) and thus allow the propagation of A-AML cells.
Genomic abnormalities and deregulated expres-
sion of genes involved in the protein ubiquitination and 
degradation pathway and in metabolism may sustain 
the process.1,2,36 The first maintains protein homeo-
stasis, as suggested by the comparable levels of protein 
ubiquitination between aneuploid and euploid cases. 
Figure 6. Mechanisms that potentially induce and support aneuploidy in AML: a model incorporating the genomic and 
transcriptomic results. AML indicates acute myeloid leukemia; SAC, spindle assembly checkpoint.
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Moreover, CN gains of genes involved in responses to 
ROS, glucose uptake/catabolism, and biosynthetic pro-
cesses may help in facing ROS accumulation, which 
causes oxidative DNA damage,47 and support energy 
metabolism in A-AML.1
Our findings may be relevant to the design of 
ad hoc therapeutic strategies that take advantage of 
aneuploid cell dependency on chaperone pathways, 
protein turnover, heightened metabolism, and a de-
regulated cell cycle. Although drugs inhibiting some 
of these cellular functions have shown poor activ-
ity (eg, NCT00666588 and NCT00830518) and/or 
an adverse risk-benefit ratio (eg, NCT01721876 and 
NCT02030405) in previous trials, pretreatment omics 
analyses may favor the selection of patient subgroups 
that will likely benefit from these targeted agents in 
the near future. Novel biological insights into disease 
mechanisms, such as those obtained in our study, could 
boost the development of new personalized medicine–
based trials. Moreover, our results suggest potential 
targets for multidrug regimens based on the concept 
of synthetic lethality. Candidate strategies include a 
combination of microtubule depolymerizing drugs and 
PLK1 inhibitors, which drove BCL2 inactivation in a 
rhabdomyosarcoma model,48 dual topoisomerase I and 
CHK1 inhibition, which achieved a curative response 
in the context of decreased expression of RAD50 in 
carcinoma,49 and simultaneous targeting of glycolytic 
metabolism and Aurora kinases, which killed AML 
cells.50 CDC20 is also a promising target for antican-
cer therapies,51 and preclinical data suggest that chem-
ical inhibition of APC/C alone or in combination with 
topoisomerase poisons52 or defective sister chromatid 
cohesion53 may be explored as potential synthetic lethal 
strategies under the aneuploid condition.
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